MacroGenics因涉嫌对MGC018用于mCRPC的2期TAMARACK研究数据的误导性陈述而面临集体诉讼。 MacroGenics faces a class-action lawsuit over alleged misleading statements about Phase 2 TAMARACK study data of MGC018 for mCRPC.
MacroGenics, Inc.(MGNX)面临一项集体诉讼,指控关于第二阶段TAMARACK研究数据的误导性陈述,该研究数据涉及MGC018(Vobra duo)抗转移性剖析-抗前列腺癌抗体-药物综合体(MCRPC)。 MacroGenics, Inc. (MGNX) faces a class-action lawsuit over alleged misleading statements regarding Phase 2 TAMARACK study data of antibody-drug conjugate MGC018 (vobra duo) for metastatic castration-resistant prostate cancer (mCRPC). 诉讼要求该公司误导投资者了解临时安全数据,导致股票价格暴涨,随后在披露5名病人死亡后下降。 The lawsuit claims the company misled investors about interim safety data, causing a share price surge followed by a decline after disclosing five patient deaths. Hagens Berman正在主持诉讼,投资者可以作为原告参与诉讼,直到2024年9月24日。 Hagens Berman is leading the lawsuit, and investors may join as plaintiffs until September 24, 2024.